Acute Gout Management with Febuxostat

First-Line Treatments for Acute Gout

The American College of Physicians recommends corticosteroids as first-line therapy in patients without contraindications due to their safety profile and low cost 1
The American College of Rheumatology suggests NSAIDs are effective as a class for reducing pain in acute gout, regardless of the specific NSAID chosen 1
The American College of Rheumatology recommends colchicine at lower doses (1.2 mg at first sign of flare, followed by 0.6 mg one hour later) is as effective as higher doses with fewer adverse effects 2

The American College of Physicians indicates febuxostat is for long-term management of hyperuricemia in patients with gout, not for acute attack treatment 3, 4
High-quality evidence shows that urate-lowering therapy (including febuxostat) does not reduce the risk for acute gout attacks within the first 6 months of treatment, according to the American College of Physicians 4

The American College of Physicians recommends prophylactic therapy with low-dose colchicine (0.6 mg twice daily) or NSAIDs when initiating urate-lowering therapy to reduce the risk of gout flares 5, 4
Moderate-quality evidence supports continuing prophylactic treatment for more than 8 weeks when starting urate-lowering therapy like febuxostat, as suggested by the American College of Physicians 4

The American College of Physicians found febuxostat (40 mg/day) and allopurinol (300 mg/day) are equally effective at decreasing serum urate levels 4
The American College of Physicians notes febuxostat is associated with adverse effects including abdominal pain, diarrhea, and musculoskeletal pain 3
The American College of Physicians states allopurinol is associated with rash and, rarely, severe hypersensitivity reactions 6

The American College of Physicians recommends using corticosteroids, NSAIDs, or colchicine as first-line therapy for acute gout attacks 1
The American College of Physicians and the American College of Rheumatology suggest not initiating febuxostat as primary treatment for the acute attack 1, 2
The American College of Physicians considers urate-lowering therapy (including febuxostat) for patients with recurrent gout (≥2 episodes per year) 4
The American College of Physicians recommends providing prophylaxis with colchicine or NSAIDs for at least 8 weeks when initiating febuxostat 5, 4

The American College of Physicians warns initiating febuxostat without concurrent anti-inflammatory prophylaxis can increase the risk of gout flares 4
The American College of Physicians notes monitoring serum urate levels is common practice, though evidence for a "treat-to-target" approach versus symptom-based management is still evolving 5